806 related articles for article (PubMed ID: 18510491)
1. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
2. Have angiotensin receptor blockers lived up to expectations?
Fitchett D
Can J Cardiol; 2005 May; 21(7):569-75. PubMed ID: 15940354
[TBL] [Abstract][Full Text] [Related]
3. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
4. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
6. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
Dzau V
J Hypertens Suppl; 2005 Apr; 23(1):S9-17. PubMed ID: 15821452
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
8. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
9. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
[TBL] [Abstract][Full Text] [Related]
10. Heart failure: is there a role for angiotensin II receptor blockers?
Boucher M; Ma J
Issues Emerg Health Technol; 2002 Sep; (38):1-4. PubMed ID: 12243202
[TBL] [Abstract][Full Text] [Related]
11. Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.
Song JH; Cha SH; Hong SB; Kim DH
J Hypertens Suppl; 2006 Mar; 24(1):S101-6. PubMed ID: 16601562
[TBL] [Abstract][Full Text] [Related]
12. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
Jorde UP
Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
[TBL] [Abstract][Full Text] [Related]
13. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
Leenen FH
Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
[TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin system modulation: the weight of evidence.
Brown B; Hall AS
Am J Hypertens; 2005 Sep; 18(9 Pt 2):127S-133S. PubMed ID: 16125049
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hypertension in chronic kidney disease.
Toto RD
Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
17. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
Carson PE
Am Heart J; 2000 Sep; 140(3):361-6. PubMed ID: 10966531
[TBL] [Abstract][Full Text] [Related]
18. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
Azadpour M; Lamas GA
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
[TBL] [Abstract][Full Text] [Related]
19. Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage.
Coca A
Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):147-59. PubMed ID: 17338661
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
Weber MA
J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):62-73. PubMed ID: 12806587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
